PL3377089T3 - Kompozycje zawierające cdnf do zastosowania do donosowego leczenia chorób ośrodkowego układu nerwowego - Google Patents
Kompozycje zawierające cdnf do zastosowania do donosowego leczenia chorób ośrodkowego układu nerwowegoInfo
- Publication number
- PL3377089T3 PL3377089T3 PL16809895T PL16809895T PL3377089T3 PL 3377089 T3 PL3377089 T3 PL 3377089T3 PL 16809895 T PL16809895 T PL 16809895T PL 16809895 T PL16809895 T PL 16809895T PL 3377089 T3 PL3377089 T3 PL 3377089T3
- Authority
- PL
- Poland
- Prior art keywords
- cdnf
- compositions
- nervous system
- central nervous
- system diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20155857 | 2015-11-18 | ||
EP16809895.2A EP3377089B1 (en) | 2015-11-18 | 2016-11-18 | Compositions comprising cdnf for use in the intranasal treatment of central nervous system diseases |
PCT/FI2016/050813 WO2017085362A1 (en) | 2015-11-18 | 2016-11-18 | Compositions comprising cdnf or manf for use in the intranasal treatment of central nervous system diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3377089T3 true PL3377089T3 (pl) | 2020-06-29 |
Family
ID=57543060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL16809895T PL3377089T3 (pl) | 2015-11-18 | 2016-11-18 | Kompozycje zawierające cdnf do zastosowania do donosowego leczenia chorób ośrodkowego układu nerwowego |
Country Status (6)
Country | Link |
---|---|
US (1) | US20190192629A1 (pl) |
EP (1) | EP3377089B1 (pl) |
JP (1) | JP7201432B2 (pl) |
ES (1) | ES2789723T3 (pl) |
PL (1) | PL3377089T3 (pl) |
WO (1) | WO2017085362A1 (pl) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110499330A (zh) * | 2018-05-16 | 2019-11-26 | 上海市同济医院 | 重组腺相关病毒载体及其应用 |
EP3838912A1 (en) * | 2019-12-20 | 2021-06-23 | Herantis Pharma Oyj | Retro-inverso peptides |
WO2021160938A1 (en) | 2020-02-13 | 2021-08-19 | Herantis Pharma Oyj | Systemic administration of a pharmaceutical composition comprising cdnf or manf polypeptide for use in the treatment of reperfusion injury |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5624898A (en) | 1989-12-05 | 1997-04-29 | Ramsey Foundation | Method for administering neurologic agents to the brain |
EP1137401B1 (en) * | 1998-12-09 | 2005-11-23 | Chiron Corporation | Administration of neurotrophic agents to the central nervous system |
ATE283286T1 (de) * | 2000-05-31 | 2004-12-15 | Us Gov Health & Human Serv | Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion |
EP1373502B8 (en) * | 2001-03-20 | 2010-12-22 | Amarantus Therapeutics, Inc. | Dopaminergic neuronal survival-promoting factors and uses thereof |
WO2007068784A1 (en) | 2005-12-14 | 2007-06-21 | Licentia Ltd | Novel neurotrophic factor protein and uses thereof |
NZ581205A (en) * | 2005-02-23 | 2011-06-30 | Alza Corp | Intranasal administration of active agents to the central nervous system |
WO2008147434A1 (en) | 2006-10-19 | 2008-12-04 | The Regents Of The University Of California | TREATMENT AND PREVENTION OF CHRONIC ASTHMA USING ANTAGONISTS OF INTEGRIN αVβ6 |
FI20080326A0 (fi) | 2008-04-30 | 2008-04-30 | Licentia Oy | Neurotroofinen tekijä MANF ja sen käytöt |
RU2612506C2 (ru) | 2011-03-03 | 2017-03-09 | Импел Ньюрофарма Инк. | Устройство для назальной доставки лекарственных средств |
FI20115870A0 (fi) | 2011-09-05 | 2011-09-05 | Urmas Arumaee | Neuroprotektiiviset soluihin tunkeutuvat peptidit |
WO2014066686A1 (en) | 2012-10-24 | 2014-05-01 | Amarantus Bioscience Holdings, Inc. | Brain targets for neurotrophic factors to treat neurodegenerative disease |
-
2016
- 2016-11-18 JP JP2018526620A patent/JP7201432B2/ja active Active
- 2016-11-18 EP EP16809895.2A patent/EP3377089B1/en active Active
- 2016-11-18 US US15/777,222 patent/US20190192629A1/en not_active Abandoned
- 2016-11-18 PL PL16809895T patent/PL3377089T3/pl unknown
- 2016-11-18 WO PCT/FI2016/050813 patent/WO2017085362A1/en active Application Filing
- 2016-11-18 ES ES16809895T patent/ES2789723T3/es active Active
Also Published As
Publication number | Publication date |
---|---|
WO2017085362A1 (en) | 2017-05-26 |
JP2018538275A (ja) | 2018-12-27 |
EP3377089A1 (en) | 2018-09-26 |
EP3377089B1 (en) | 2020-04-08 |
ES2789723T3 (es) | 2020-10-26 |
JP7201432B2 (ja) | 2023-01-10 |
US20190192629A1 (en) | 2019-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201901279B (en) | Compositions and methods for treatment of neurological disorders | |
HK1258588A1 (zh) | 用於治療眼科疾病的化合物和製劑 | |
IL285151B1 (en) | Methods for the treatment of fgf21-related disorders | |
HK1231417A1 (zh) | 用於治療眼科疾病和障礙的化合物 | |
SG11201705093UA (en) | Composition for treating il-6-related diseases | |
IL246791A0 (en) | Compositions and methods for treating eye diseases | |
HK1243325A1 (zh) | 用於治療視覺障礙的組合物和方法 | |
PL3277280T3 (pl) | Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych | |
HK1245127A1 (zh) | 治療腦疾病的方法和組合物 | |
GB201404403D0 (en) | Compositions and methods relating to the treatment of diseases | |
HK1258994A1 (zh) | 用於疾病治療的方法 | |
GB201408387D0 (en) | Treatment of respiratory disorders | |
PT3160464T (pt) | 6-hidroxibuspirona para uso no tratamento de transtornos do movimento | |
IL259710A (en) | Preparations and methods for the treatment of Davidson's disease (microvillus inclusion disease) and related diseases | |
IL251736B (en) | Methods and compositions for the treatment of radiation-related disorders | |
GB201612043D0 (en) | Composition for treatment of disorders | |
GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
PL3377089T3 (pl) | Kompozycje zawierające cdnf do zastosowania do donosowego leczenia chorób ośrodkowego układu nerwowego | |
IL259381B (en) | Miravegron for the treatment of retinal diseases | |
HK1244782A1 (zh) | 用於治療疾病和病癥的組合物和方法 | |
HK1243937A1 (zh) | 治療疾病的方法 | |
EP3200795A4 (en) | Use of agents for treating fat-related disorders | |
GB201602784D0 (en) | New treatment of CFTR-related disorders | |
ZA201408464B (en) | Composition for the use in treatment of asthma |